#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz

News

:IMPORT-LR:

Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months

3. 2. 2020 Source: Wound Healing

The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending physicians and surgeons. Authors of a recently published study have addressed the risk factors, clinical symptoms, and, last but not least, the therapy outcomes of chronic leg ulcers lasting more than 6 months.

LDL cholesterol

LDL cholesterol: a new risk factor for the onset of venous thromboembolic disease?

Not only do atherosclerotic plaques in the arteries and the risk of heart attack decrease along with LDL cholesterol levels. Results from a large molecular genetic study suggest that lowering its…
3. 2. 2020 Source: Cardiovascular Risks

Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In…
3. 2. 2020 Source: Non-Hodgkin Lymphomas and CLL
zhodnocení výsledků vyšetření u lékaře 2356x1571

End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma

The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA ×…
2. 2. 2020 Source: Prostate Health Index
notebook_studie_výzkum_laptop_vzdělávání

Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker

The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer…
2. 2. 2020 Source: Prostate Health Index

Cardiovascular Benefit of SGLT2 Inhibitors Confirmed

The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a...
31. 1. 2020 Source: Diabetes
muz_zena_par

Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?

Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less…
31. 1. 2020 Source: Cardiovascular Risks
obezita_lide_ulice

Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients

Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis…
28. 1. 2020 Source: Thromboprophylaxis
PL_operace_lekari_monitor

Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity

Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often…
28. 1. 2020 Source: Thromboprophylaxis
biomarker_rakovina_vyzkum_lymfom

Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients…
27. 1. 2020 Source: Non-Hodgkin Lymphomas and CLL
samovysetreni_prsa

Kadcyla in a New Indication –⁠ Adjuvant Therapy for Early HER2+ Breast Cancer

In December, the European Commission approved the expansion of the indication for Roche's medicinal product Kadcyla, which contains the active substance trastuzumab emtansine. This expansion makes…
23. 1. 2020 Source: Breast Carcinoma

Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist −⁠ NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of…
20. 1. 2020 Source: Antiemetic Therapy

Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of…
20. 1. 2020 Source: Antiemetic Therapy
http://freerangestock.com/

Impact of Oral Antidiabetics on Heart Failure

Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes...
19. 1. 2020 Source: Diabetes
Matka s kašlající dcerou u lékařky

Position of Levodropropizine in Cough Therapy

An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using…
15. 1. 2020 Source: Cough Therapy
1 … 111 112 113 114 115
Filter by speciality
Remove filters
Popular this week
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#